» Articles » PMID: 11459780

Differential Regulation of the Human Sodium/iodide Symporter Gene Promoter in Papillary Thyroid Carcinoma Cell Lines and Normal Thyroid Cells

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2001 Jul 19
PMID 11459780
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The absence of TSH-stimulated radioiodide uptake in differentiated thyroid cancer is associated with a high recurrence rate and reduced survival. We studied regulation of the sodium/iodide symporter gene in human papillary thyroid cancer cell lines (BHP) and primary human thyroid cells. BHP cells expressed very low levels of sodium/iodide symporter mRNA and did not concentrate iodide, but iodide uptake was restored to levels seen in FRTL-5 rat thyroid cells by stable transfection of a sodium/iodide symporter cDNA. Sodium/iodide symporter gene expression, therefore, was necessary and sufficient for iodide uptake in BHP cells. We cloned the human sodium/iodide symporter gene 5'-flanking region and analyzed progressive 5'-deletions in transient transfections. We identified a region, -596 to -268, essential to confer full promoter activity in primary normal human thyroid cells. Sodium/iodide symporter promoter activity in four BHP cell lines, however, was markedly reduced, consistent with down-regulation of the endogenous sodium/iodide symporter gene. Nuclear extracts from BHP 2-7 cells had reduced or absent binding to regions of the sodium/iodide symporter promoter shown to be critical for expression, compared with nuclear extracts from FRTL-5 cells. Competition studies indicated that these nuclear proteins were not known thyroid transcription factors. Modifications of the sodium/iodide symporter promoter with demethylation or histone acetylation did not increase sodium/iodide symporter expression, and no deletions of the critical regulatory region were identified in the endogenous gene in BHP cells. Regulation of the sodium/iodide symporter 5'-flanking region in transient transfection paralleled endogenous sodium/iodide symporter expression. Reduced expression of potential novel nuclear factor(s) in these cell lines may contribute to reduced sodium/iodide symporter expression resulting in absence of iodide uptake in some papillary thyroid cancers.

Citing Articles

Differentiation of benign and malignant lesions in Bethesda III and IV thyroid nodules via dual-energy computed tomography quantitative parameters and morphologic features.

Ren X, Song Z, Zhang D, Li X, Huang J, Liu Q Quant Imaging Med Surg. 2024; 14(7):4567-4578.

PMID: 39022257 PMC: 11250302. DOI: 10.21037/qims-23-1511.


Detection of malignant lesions in cytologically indeterminate thyroid nodules using a dual-layer spectral detector CT-clinical nomogram.

Ren X, Zhang J, Song Z, Li Q, Zhang D, Li X Front Oncol. 2024; 14:1357419.

PMID: 38863637 PMC: 11165073. DOI: 10.3389/fonc.2024.1357419.


Dual-source dual-energy computed tomography-derived quantitative parameters combined with machine learning for the differential diagnosis of benign and malignant thyroid nodules.

Jiang L, Liu D, Long L, Chen J, Lan X, Zhang J Quant Imaging Med Surg. 2022; 12(2):967-978.

PMID: 35111598 PMC: 8739151. DOI: 10.21037/qims-21-501.


Identification of benign and malignant thyroid nodules by in vivo iodine concentration measurement using single-source dual energy CT: A retrospective diagnostic accuracy study.

Gao S, Zhang X, Wei W, Li X, Li Y, Xu M Medicine (Baltimore). 2016; 95(39):e4816.

PMID: 27684811 PMC: 5265904. DOI: 10.1097/MD.0000000000004816.


Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.

Xia W, Li D, Wang G, Ni J, Zhuang J, Ha M Cancer Gene Ther. 2016; 23(10):333-340.

PMID: 27608773 DOI: 10.1038/cgt.2016.36.